Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic (PK) Exposure of 4-Hydroxycyclophosphamide Associates with Clinical Benefits of Reduced-Dose Post-Transplantation Cyclophosphamide: Results of a Completed Phase I/II Trial to De-Escalate Post-Transplantation Cyclophosphamide for HLA-Haploidentical Myeloablative Bone Marrow Transplantation

Blood (2024) 144 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2024-212138

Published: 2024

Journal Articles

Characteristics and Risk Factors for BK Virus-Associated Cystitis after Post-Transplant Cyclophosphamide (PTCy) -Based Allogeneic Hematopoietic Cell Transplants (HCT)

Elisabetta Xue, Dimana Dimitrova, Hyoyoung Choo-Wosoba, Rechache Kamil, Ruby Sabina, Christi McKeown, Alison Cusmano, Mustafa A. Hyder, Christopher G. Kanakry, Jennifer A. Kanakry

Blood (2024) 144 (Supplement 1): 689.

https://doi.org/10.1182/blood-2024-208193

Published: 2024

Journal Articles

Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Cynthia Eleanya, Stacey Doran, Amy Chai, Rebecca Schwartz, Jessica Andrade, Dimana Dimitrova, Jennifer Hendricks, Mustafa A. Hyder, Rechache Kamil, Ruby Sabina, Jennifer Sponaugle, Christopher G. Kanakry, Jennifer A. Kanakry

Blood (2024) 144 (Supplement 1): 2429.

https://doi.org/10.1182/blood-2024-205625

Published: 2024

Journal Articles

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma - a Bridge to Transplant and an Effective Salvage for the Unfit

Matko Kalac, Salvia Jain, Constantine S. Tam, Mendel Goldfinger, Zhengrui Xiao, Francesca Montanari, Bryan D. Huber, Jennifer A. Kanakry, Owen A. O'Connor, Enrica Marchi

Blood (2022) 140 (Supplement 1): 9422–9424.

https://doi.org/10.1182/blood-2022-165165

Published: 2022

Journal Articles

Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation

Meredith J. McAdams, Mustafa Hyder, Dimana Dimitrova, Jennifer L. Sadler, Christi McKeown, Seth M. Steinberg, Amy Chai, Scott Napier, Anita Stokes, Jennifer Sponaugle, Thomas E. Hughes, Nu Ri Cha, Jennifer Cuellar-Rodriguez, Melissa Walker, Ronald E. Gress, Jennifer A. Kanakry, Christopher G. Kanakry

Blood (2021) 138 (Supplement 1): 101.

https://doi.org/10.1182/blood-2021-146997

Published: 2021

Journal Articles

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

Matko Kalac, Constantine S. Tam, Mendel Goldfinger, Zhengrui Xiao, Francesca Montanari, Jennifer A. Kanakry, Owen A. O'Connor, Enrica Marchi

Blood (2021) 138 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2021-144651

Published: 2021

Journal Articles

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Blood (2021) 137 (23): 3291–3305.

https://doi.org/10.1182/blood.2020009362

Published: 2021

Includes: Supplemental data

Journal Articles

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Jennifer Brudno, MD, Steven Hartman, Norris Lam, BS, David F. Stroncek, John M. Rossi, MS, Yueh-wei Shen, Allen Xue, PhD, Adrian Bot, MD PhD, Jennifer A Kanakry, MD, Steven Z. Pavletic, MD, Lekha Mikkilineni, MD, Mark Roschewski, MD, Robert M. Dean, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Steve A. Rosenberg, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2018) 132 (Supplement 1): 697.

https://doi.org/10.1182/blood-2018-99-113731

Published: 2018

Journal Articles

Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7

Scott Michael Norberg, DO, Nisha Nagarsheth, PhD, Stacey Doran, MD, Jennifer A Kanakry, MD, Sabina Adhikary, PhD, Colleen Schweitzer, PhD, Stephanie H Astrow, PhD, William Faquin, MD, Nikolaos Gkitsas, Steven Highfill, PhD, Christian S Hinrichs

Blood (2018) 132 (Supplement 1): 492.

https://doi.org/10.1182/blood-2018-99-117017

Published: 2018

Journal Articles

Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers

Blood (2017) 130 (Supplement 1): 375.

https://doi.org/10.1182/blood.V130.Suppl_1.375.375

Published: 2017

Journal Articles

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Jennifer Brudno, MD, Norris Lam, BS, Michael Wang, MD, David Stroncek, MD, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Steven Hartman, Jennifer A. Kanakry, MD, Steven Z. Pavletic, MD, Steven A. Feldman, Judith Lawrence, Rashmika Patel, Brenna Hansen, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 524.

https://doi.org/10.1182/blood.V130.Suppl_1.524.524

Published: 2017

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

Journal Articles

Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study

Blood (2016) 128 (22): 4145.

https://doi.org/10.1182/blood.V128.22.4145.4145

Published: 2016

Journal Articles

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

Blood (2016) 128 (22): 2992.

https://doi.org/10.1182/blood.V128.22.2992.2992

Published: 2016

Journal Articles

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

Jennifer N. Brudno, MD, Victoria Shi, David Stroncek, MD, Stefania Pittaluga, MD PhD, Jennifer A. Kanakry, MD, Lauren M. Curtis, MD, Juan C. Gea-Banacloche, MD, Steven Pavletic, MD, Mohammad-Hadi Bagheri, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2016) 128 (22): 999.

https://doi.org/10.1182/blood.V128.22.999.999

Published: 2016

Journal Articles

The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases

Jennifer A. Kanakry, Aparna M. Hegde, Christine M. Durand, Allan B. Massie, Amy E. Greer, Richard F. Ambinder, Alexandra Valsamakis

Blood (2016) 127 (16): 2007–2017.

https://doi.org/10.1182/blood-2015-09-672030

Published: 2016

Includes: Supplemental data

Journal Articles

Might haplo “be the (better) match”?

Jennifer A. Kanakry, Leo Luznik

Blood (2016) 127 (7): 799–800.

https://doi.org/10.1182/blood-2016-01-689042

Published: 2016

Journal Articles

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood (2015) 125 (19): 3024–3031.

https://doi.org/10.1182/blood-2015-01-623991

Published: 2015

Includes: Supplemental data

Journal Articles

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Blood (2014) 124 (25): 3817–3827.

https://doi.org/10.1182/blood-2014-07-587477

Published: 2014

Includes: Supplemental data

Journal Articles

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel, Hua-Ling Tsai, Javier Bolaños-Meade, Christopher G. Kanakry, Douglas E. Gladstone, Leo Luznik, Carol Ann Huff, Lode J. Swinnen, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs, Yvette L. Kasamon

Blood (2014) 124 (21): 680.

https://doi.org/10.1182/blood.V124.21.680.680

Published: 2014

NARROW

Characteristics and Risk Factors for BK Virus-Associated Cystitis after Post-Transplant Cyclophosphamide (PTCy) -Based Allogeneic Hematopoietic Cell Transplants (HCT)

Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma - a Bridge to Transplant and an Effective Salvage for the Unfit

Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7

Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases

Might haplo “be the (better) match”?

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only